compassionate use program
Coverage of compassionate use program in the Nexus archive.
- What is pulmonary hypertension and why would a new GLP-1 help?
A 79-year-old patient with obesity, sleep apnea, and pulmonary hypertension received Eli Lilly's experimental drug retatrutide under a compassionate use program. The White House denied the drug was for President Trump after initial speculation.
- White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
The White House denied that Trump gained access to Eli Lilly's unapproved obesity drug retatrutide through a compassionate use program. The drug, not yet FDA approved, is available via a program that provides experimental treatments for life-threatening illnesses.
- STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
Eli Lilly and the FDA have allowed one person to receive the company's obesity drug retatrutide through the FDA's 'compassionate use' program. The access was granted via an exclusive report by Lizzy Lawrence.
- STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?
Eli Lilly provided access to its experimental obesity drug retatrutide to a 79-year-old man through the FDA’s compassionate use program. The case drew interest from top health officials, suggesting the recipient was well connected.